Skin and soft tissue infection caused by Achromobacter xylosoxidans: Report of 14 cases

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 2, 2014, Pages 130-135

  Tena, Daniel ^a   Martínez, Nora Mariela ^a   Losa, Cristina ^a   Solís, Sonia ^a  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

Achromobacter denitrificans; Achromobacter xylosoxidans; Alcaligenes species; Skin infection; Soft tissue infection; Surgical site infection; Wound infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; WATER;

ACHROMOBACTER XYLOSOXIDANS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CLINICAL ARTICLE; COMMUNICABLE DISEASE; FEMALE; FOOT ULCER; HUMAN; ISCHEMIA; LEG ULCER; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT CARE; RETROSPECTIVE STUDY; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; SPAIN; SURGICAL INFECTION; TOTAL KNEE REPLACEMENT; UNIVERSITY HOSPITAL; VERY ELDERLY; WOUND DRESSING; WOUND INFECTION; YOUNG ADULT;

ACHROMOBACTER DENITRIFICANS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892629719     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.857043     Document Type: Article

References (26)

1. PC, Daneshvar MI, Hollis DG. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative Gram-negative rods. In: Murray PR, Baron JE, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of clinical microbiology. Washington DC: ASM Press; 2007 pp 770-802.
2. Yabuuchi E, Oyama A. Achromobacter xylosoxidansn. sp. from human ear discharge. J pn J Microbiol 1971; 15: 477-81.
3. Ridderberg W, Wang M, Norskov-Lauritsen N. Multilocus sequence analysis of isolates from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans. J Clin Microbiol 2012; 50: 2688-94.
4. Igra-Siegman Y, Chmel H, Cobbs C. Clinical and laboratory characteristics of Achromobacter xylosoxidans infection. J Clin Microbiol 1980; 11: 141-5.
5. Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis 1996; 23: 569-76.
6. Tena D, Carranza R, Barberá JR, Valdezate S, Garrancho JM, Arranz M, et al. Outbreak of long-term intravascular catheter-related bacteremia due to Achromobacter xylosoxidans subspecies xylosoxidans in a hemodialysis unit. Eur J Clin Microbiol Infect Dis 2005; 24: 727-32.
7. Reina J, Antich M, Siquier B, Alomar P. Nosocomial outbreak of Achromobacter xylosoxidans associated with a diagnostic contrast solution. J Clin Pathol 1988; 41: 920-3.
8. Gahrn-Hansen B, Alstrup P, Dessau R, Fursted K, Knudsen A, Olsen H, et al. Outbreak of infection with Achromobacter xylosoxidans from contaminated intravascular pressure transducers. J Hosp Infect 1988; 12: 1-6.
9. Aisenberg G, Rolston KV, Safdar A. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer 2004; 101: 2134-40.
10. Shie SS, Huang CT, Leu H S. Characteristics of Achromobacter xylosoxidans bacteremia in northern Taiwan. J Microbiol Immunol Infect 2005; 38: 277-82.
11. Otto-Karg I, Jandl S, Müller T, Stirzel B, Frosch M, Hebestreit H, et al. Validation of Vitek 2 nonfermenting Gram-negative cards and Vitek 2 version 4.02 software for identification and antimicrobial susceptibility testing of nonfermenting Gram-negative rods from patients with cystic fi brosis. J Clin Microbiol 2009; 47: 3283-8.
12. Eron LJ, Lipsky BA, Low DE, Nathwabi D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52: 3-17.
13. Garner JS, Jarvis R, Emori TG, Horan TC, Hughes J M. CDC defi nitions for nosocomial infections. Am J Infect Control 1988; 16: 128-40.
14. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis W R. Guideline for prevention of surgical site infection. Infect Control Hosp Epidemiol 1999; 20: 250-78.
15. Holmes B, Snell JJS, Lapage SP. Strains of Achromobacter xylosoxidans from clinical material. J Clin Pathol 1977; 30: 595-601.
16. Pien FD, Higa H Y. Achromobacter xylosoxidans isolates in Hawaii. J Clin Microbiol 1978; 7: 239-41.
17. Spear JB, Fuhrer J, Kirby B D. Achromobacter xylosoxidans (Alcaligenes xylosoxidans subsp. xylosoxidans) bacteremia associated with a well-water source: case report and review of the literature. J Clin Microbiol 1988; 26: 598-9.
18. York JC, Lisse JR. Achromobacter xylosoxidans septic arthritis in a patient with systemiclupus erythematous. Arthritis Rheum 1991; 34: 1484-5.
19. Legrand C, Anaissie E. Bacteremia due to Achromobacter xylosoxidans in patients with cancer. Clin Infect Dis 1992; 14: 479-84.
20. Tsay RW, Lin LC, Chiou CS, Liao JC, Chen CH, Liu CE, et al. Alcaligenes xylosoxidans bacteremia: clinical features and microbiological characteristics of isolates. J Microbiol Immunol Infect 2005; 38: 194-9.
21. Eshwara VK, Mukhopadhyay C, Mohan S, Prakash R, Pai G. Two unique presentations of Achromobacter xylosoxidans infections in clinical settings. J Infect Dev Ctries 2011; 5: 138-41.
22. Schoch PE, Cunha B A. Nosocomial Achromobacter xylosoxidans infections. Infect Control Hosp Epidemiol 1988; 9: 84-7.
23. Vu-Thien H, Darbord JC, Moissenet D, Dulot C, Dufourcq JB, Marsol P, et al. Investigation of an outbreak of wound infections due to Alcaligenes xylosoxidans transmitted by chlorhexidine in a burn unit. Eur J Clin Microbiol Infect Dis 1998; 17: 724-6.
24. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004; 39: S104-14.
25. Burns JL, Saiman L, Whittier S, Krzewinski L. Z, Larone D, et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fi brosis patients. Diagn Microbiol Infect Dis 2001; 39: 257-60.
26. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cysticfibrosis. Antimicrob Agents Chemother 2002; 46: 1105-7.